Crestchem Ltd
Incorporated in 1991, Crestchem Ltd is in
the field of processing, manufacturing, and trading and marketing, of specialty chemical
ingredients,[1]
- Market Cap ₹ 36.5 Cr.
- Current Price ₹ 122
- High / Low ₹ 329 / 110
- Stock P/E 18.0
- Book Value ₹ 26.9
- Dividend Yield 0.82 %
- ROCE 59.9 %
- ROE 44.1 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 44.8%
Cons
- Promoter holding is low: 29.7%
- Debtor days have increased from 21.4 to 37.4 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.42 | 0.09 | 0.13 | 0.14 | 0.05 | 0.10 | 6.15 | 7.62 | 7.90 | 16.66 | 21.18 | 24.98 | 24.25 | |
| 0.36 | 0.23 | 0.18 | 0.34 | 0.29 | 0.26 | 5.59 | 6.95 | 7.15 | 15.84 | 18.40 | 21.66 | 22.03 | |
| Operating Profit | 0.06 | -0.14 | -0.05 | -0.20 | -0.24 | -0.16 | 0.56 | 0.67 | 0.75 | 0.82 | 2.78 | 3.32 | 2.22 |
| OPM % | 14.29% | -155.56% | -38.46% | -142.86% | -480.00% | -160.00% | 9.11% | 8.79% | 9.49% | 4.92% | 13.13% | 13.29% | 9.15% |
| 0.03 | 0.89 | 0.19 | 0.08 | 0.03 | 0.02 | 0.03 | 0.05 | 0.08 | 0.15 | 0.26 | 0.44 | 0.51 | |
| Interest | 0.03 | 0.02 | 0.02 | 0.04 | 0.01 | 0.01 | 0.00 | 0.02 | 0.02 | 0.01 | 0.01 | 0.05 | 0.00 |
| Depreciation | 0.08 | 0.05 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.02 | 0.03 | 0.02 | 0.05 | 0.05 | 0.07 |
| Profit before tax | -0.02 | 0.68 | 0.12 | -0.16 | -0.22 | -0.16 | 0.57 | 0.68 | 0.78 | 0.94 | 2.98 | 3.66 | 2.66 |
| Tax % | 0.00% | 10.29% | 25.00% | 0.00% | -13.64% | 0.00% | 22.81% | 14.71% | 26.92% | 26.60% | 27.85% | 25.41% | |
| -0.03 | 0.61 | 0.09 | -0.16 | -0.19 | -0.17 | 0.44 | 0.57 | 0.57 | 0.69 | 2.15 | 2.73 | 2.02 | |
| EPS in Rs | -0.10 | 2.03 | 0.30 | -0.53 | -0.63 | -0.57 | 1.47 | 1.90 | 1.90 | 2.30 | 7.17 | 9.10 | 6.73 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 6.98% | 10.99% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 76% |
| 5 Years: | 32% |
| 3 Years: | 47% |
| TTM: | -7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 34% |
| 5 Years: | 44% |
| 3 Years: | 69% |
| TTM: | -36% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 13% |
| 3 Years: | 22% |
| 1 Year: | -54% |
| Return on Equity | |
|---|---|
| 10 Years: | 35% |
| 5 Years: | 44% |
| 3 Years: | 45% |
| Last Year: | 44% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| Reserves | -2.59 | -2.09 | -2.00 | -2.16 | -2.36 | -2.53 | -2.08 | -1.51 | -0.94 | -0.25 | 1.90 | 4.48 | 5.07 |
| 0.40 | 0.37 | 0.35 | 0.60 | 0.14 | 0.28 | 0.02 | 0.63 | 0.27 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.49 | 0.22 | 0.05 | 0.05 | 0.04 | 0.14 | 1.35 | 0.87 | 0.96 | 2.04 | 2.24 | 3.07 | 5.48 | |
| Total Liabilities | 1.30 | 1.50 | 1.40 | 1.49 | 0.82 | 0.89 | 2.29 | 2.99 | 3.29 | 4.79 | 7.14 | 10.55 | 13.55 |
| 0.46 | 0.04 | 0.04 | 0.04 | 0.11 | 0.12 | 0.10 | 0.14 | 0.11 | 0.10 | 0.17 | 0.26 | 0.23 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.84 | 1.46 | 1.36 | 1.45 | 0.71 | 0.77 | 2.19 | 2.85 | 3.18 | 4.69 | 6.97 | 10.29 | 13.32 | |
| Total Assets | 1.30 | 1.50 | 1.40 | 1.49 | 0.82 | 0.89 | 2.29 | 2.99 | 3.29 | 4.79 | 7.14 | 10.55 | 13.55 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.10 | 0.05 | -0.27 | -0.04 | -0.70 | -0.02 | 0.33 | 0.39 | 0.82 | 2.21 | 0.35 | 1.55 | |
| 0.02 | 0.06 | 0.34 | 0.64 | 0.12 | 0.01 | -0.35 | -0.39 | -0.83 | -1.34 | -1.07 | -0.88 | |
| 0.07 | -0.05 | -0.02 | -0.04 | -0.01 | -0.01 | 0.00 | -0.02 | -0.02 | -0.01 | -0.01 | -0.09 | |
| Net Cash Flow | -0.01 | 0.06 | 0.05 | 0.55 | -0.58 | -0.02 | -0.02 | -0.01 | -0.02 | 0.86 | -0.72 | 0.59 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 356.31 | 0.00 | 336.92 | 469.29 | 730.00 | 292.00 | 71.81 | 67.54 | 41.58 | 0.44 | 26.37 | 37.41 |
| Inventory Days | 0.00 | 60.83 | 0.00 | 73.00 | 0.00 | 182.50 | 0.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days Payable | 60.83 | 73.00 | 365.00 | 91.06 | ||||||||
| Cash Conversion Cycle | 356.31 | 0.00 | 336.92 | 469.29 | 730.00 | 109.50 | -18.50 | 67.54 | 41.58 | 0.44 | 26.37 | 37.41 |
| Working Capital Days | -234.64 | -1,987.22 | -645.77 | -1,016.79 | 438.00 | -292.00 | 3.56 | 12.93 | -2.77 | -36.81 | -1.21 | 8.47 |
| ROCE % | 1.30% | -13.40% | 10.65% | -8.60% | -18.92% | -19.61% | 67.46% | 45.75% | 35.96% | 37.40% | 78.17% | 59.94% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
14 Nov - Newspaper clipping of unaudited standalone results for Q2 and H1 ended Sep 30, 2025 published Nov 14, 2025.
-
Board Meeting Outcome for Unaudied Financial Results For The Quarter & Half Year Ended On September 30,2025
12 Nov - Board approved unaudited standalone financial results and limited review for quarter and half-year ended Sep 30, 2025.
-
Board Meeting Intimation for Unaudited Financial Result For The Half Year Ended 30.09.2025 Alongwith Limited Review Report Of Auditor.
4 Nov - Board meeting on 12 Nov 2025 to approve H1 unaudited standalone results for period ended 30 Sep 2025.
-
Certificate From PCS Reg 40 (10)
9 Oct - Practising CS certificate on share capital reconciliation for half year ended Sep 30, 2025; transfers and duplicate requests processed.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Oct - Certificate under Regulation 74(5) confirming dematerialisation processing for quarter ended 30 September 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2][3]
CL specializes in manufacturing, processing, marketing, and exporting nutraceutical ingredients used in health food, personal care, and specialty chemicals. Its key products, Caprylic/Capric Triglycerides in oil and powder form, along with downstream derivatives, also have industrial applications.